{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:04:06Z","timestamp":1778861046929,"version":"3.51.4"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.lfs.2020.118142","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T21:05:41Z","timestamp":1595538341000},"page":"118142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future"],"prefix":"10.1016","volume":"257","author":[{"given":"Jishou","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menglong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2020.118142_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105924","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges","volume":"55","author":"Lai","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.lfs.2020.118142_bb0010","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.mayocp.2020.02.003","article-title":"Guide to understanding the 2019 novel coronavirus","volume":"95","author":"Shah","year":"2020","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.lfs.2020.118142_bb0015","doi-asserted-by":"crossref","first-page":"m1036","DOI":"10.1136\/bmj.m1036","article-title":"Covid-19: WHO declares pandemic because of \u201calarming levels\u201d of spread, severity, and inaction","volume":"368","author":"Mahase","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.lfs.2020.118142_bb0020","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"CELL"},{"key":"10.1016\/j.lfs.2020.118142_bb0025","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1042\/BJ20040634","article-title":"Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism","volume":"383","author":"Rice","year":"2004","journal-title":"Biochem. J."},{"key":"10.1016\/j.lfs.2020.118142_bb0030","doi-asserted-by":"crossref","first-page":"L1015","DOI":"10.1152\/ajplung.00163.2018","article-title":"ACE-2\/ANG1-7 ameliorates ER stress-induced apoptosis in seawater aspiration-induced acute lung injury","volume":"315","author":"Zhang","year":"2018","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.lfs.2020.118142_bb0035","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"LANCET"},{"key":"10.1016\/j.lfs.2020.118142_bb0040","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00547-2020","article-title":"Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis","volume":"55","author":"Guan","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lfs.2020.118142_bb0045","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.lfs.2020.118142_bb0050","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.003956","article-title":"Dose of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and outcomes in heart failure: a meta-analysis","volume":"10","author":"Khan","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.lfs.2020.118142_bb0055","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jacc.2005.09.055","article-title":"The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)","volume":"47","author":"McMurray","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.lfs.2020.118142_bb0060","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S2213-8587(14)70256-6","article-title":"Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis","volume":"3","author":"Wang","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.lfs.2020.118142_bb0065","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials","volume":"67","author":"Xie","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.lfs.2020.118142_bb0070","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/HJH.0b013e3280bad9b4","article-title":"Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system","volume":"25","author":"Turnbull","year":"2007","journal-title":"J. Hypertens."},{"key":"10.1016\/j.lfs.2020.118142_bb0075","author":"American College of Cardiology"},{"key":"10.1016\/j.lfs.2020.118142_bb0080","author":"European Society of Cardiology"},{"key":"10.1016\/j.lfs.2020.118142_bb0085","doi-asserted-by":"crossref","DOI":"10.1093\/cvr\/cvaa097","article-title":"Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19","author":"Kreutz","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.lfs.2020.118142_bb0090","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.biopha.2017.07.091","article-title":"Renin-angiotensin-aldosterone (RAAS): the ubiquitous system for homeostasis and pathologies","volume":"94","author":"Patel","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.lfs.2020.118142_bb0095","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1124\/pr.59.3.3","article-title":"The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease","volume":"59","author":"Kobori","year":"2007","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.lfs.2020.118142_bb0100","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1124\/pr.118.017129","article-title":"Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure","volume":"71","author":"Arendse","year":"2019","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.lfs.2020.118142_bb0105","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1681\/ASN.2014080816","article-title":"Vascular type 1A angiotensin II receptors control BP by regulating renal blood flow and urinary sodium excretion","volume":"26","author":"Sparks","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2020.118142_bb0110","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYPERTENSIONAHA.113.02426","article-title":"Possible role of angiotensin-converting enzyme 2 and activation of angiotensin II type 2 receptor by angiotensin-(1-7) in improvement of vascular remodeling by angiotensin II type 1 receptor blockade","volume":"63","author":"Ohshima","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.lfs.2020.118142_bb0115","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.lfs.2015.01.005","article-title":"Role of angiotensin II type 1 receptor on renal NAD(P)H oxidase, oxidative stress and inflammation in nitric oxide inhibition induced-hypertension","volume":"124","author":"Rincon","year":"2015","journal-title":"Life Sci."},{"key":"10.1016\/j.lfs.2020.118142_bb0120","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1161\/HYPERTENSIONAHA.114.03743","article-title":"Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism","volume":"64","author":"Deshotels","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.lfs.2020.118142_bb0125","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1042\/CS20130436","article-title":"Angiotensin-(1-7) and angiotensin-(1-9): function in cardiac and vascular remodelling","volume":"126","author":"McKinney","year":"2014","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.lfs.2020.118142_bb0130","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00592-011-0348-z","article-title":"Angiotensin-(1-7) suppresses oxidative stress and improves glucose uptake via Mas receptor in adipocytes","volume":"49","author":"Liu","year":"2012","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.lfs.2020.118142_bb0135","doi-asserted-by":"crossref","first-page":"L1141","DOI":"10.1152\/ajplung.00029.2016","article-title":"Chronic allergic pulmonary inflammation is aggravated in angiotensin-(1-7) Mas receptor knockout mice","volume":"311","author":"Magalhaes","year":"2016","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.lfs.2020.118142_bb0140","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bcp.2017.07.022","article-title":"Azilsartan ameliorates diabetic cardiomyopathy in young db\/db mice through the modulation of ACE-2\/ANG 1-7\/Mas receptor cascade","volume":"144","author":"Sukumaran","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.lfs.2020.118142_bb0145","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","article-title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure","volume":"436","author":"Imai","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2020.118142_bb0150","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1161\/HYPERTENSIONAHA.119.14071","article-title":"Ang II (angiotensin II) conversion to angiotensin-(1-7) in the circulation is POP (prolyloligopeptidase)-dependent and ACE2 (angiotensin-converting enzyme 2)-independent","volume":"75","author":"Serfozo","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.lfs.2020.118142_bb0155","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCRESAHA.116.310509","article-title":"Clinical relevance and role of neuronal AT1 receptors in ADAM17-mediated ACE2 shedding in neurogenic hypertension","volume":"121","author":"Xu","year":"2017","journal-title":"Circ. Res."},{"key":"10.1016\/j.lfs.2020.118142_bb0160","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1161\/HYPERTENSIONAHA.120.15082","article-title":"Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers","volume":"75","author":"Danser","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.lfs.2020.118142_bb0165","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev-virology-110615-042301","article-title":"Structure, function, and evolution of coronavirus spike proteins","volume":"3","author":"Li","year":"2016","journal-title":"Annu Rev Virol"},{"key":"10.1016\/j.lfs.2020.118142_bb0170","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nrmicro2147","article-title":"Coronaviruses post-SARS: update on replication and pathogenesis","volume":"7","author":"Perlman","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.lfs.2020.118142_bb0175","doi-asserted-by":"crossref","first-page":"11727","DOI":"10.1073\/pnas.2003138117","article-title":"Cell entry mechanisms of SARS-CoV-2","volume":"117","author":"Shang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2020.118142_bb0180","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2020.118142_bb0185","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.lfs.2020.118142_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035876","article-title":"Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts","volume":"7","author":"Bertram","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2020.118142_bb0195","first-page":"656","article-title":"Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis","volume":"80","author":"Fu","year":"2020","journal-title":"J. Inf. Secur."},{"key":"10.1016\/j.lfs.2020.118142_bb0200","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cytogfr.2020.05.003","article-title":"The cytokine storm in COVID-19: an overview of the involvement of the chemokine\/chemokine-receptor system","volume":"53","author":"Coperchini","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.lfs.2020.118142_bb0205","first-page":"607","article-title":"The pathogenesis and treatment of the \u2018Cytokine Storm\u2019 in COVID-19","volume":"80","author":"Ye","year":"2020","journal-title":"J. Inf. Secur."},{"key":"10.1016\/j.lfs.2020.118142_bb0210","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00281-017-0639-8","article-title":"Cytokine storm and sepsis disease pathogenesis","volume":"39","author":"Chousterman","year":"2017","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.lfs.2020.118142_bb0215","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40249-020-00662-x","article-title":"Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues","volume":"9","author":"Li","year":"2020","journal-title":"Infect Dis Poverty"},{"key":"10.1016\/j.lfs.2020.118142_bb0220","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2020.118142_bb0225","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1152\/physrev.00023.2016","article-title":"The ACE2\/angiotensin-(1-7)\/MAS axis of the renin-angiotensin system: focus on angiotensin-(1-7)","volume":"98","author":"Santos","year":"2018","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.lfs.2020.118142_bb0230","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/s41440-019-0271-1","article-title":"Azilsartan causes natriuresis due to its sympatholytic action in kidney disease","volume":"42","author":"Kidoguchi","year":"2019","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.lfs.2020.118142_bb0235","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00210-018-1523-3","article-title":"Modulation of brain ACE and ACE2 may be a promising protective strategy against cerebral ischemia\/reperfusion injury: an experimental trial in rats","volume":"391","author":"Abdel-Fattah","year":"2018","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.lfs.2020.118142_bb0240","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12872-018-0875-4","article-title":"Telmisartan protects chronic intermittent hypoxic mice via modulating cardiac renin-angiotensin system activity","volume":"18","author":"Wang","year":"2018","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.lfs.2020.118142_bb0245","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/ndt\/gfw105","article-title":"Fibroblast growth factor 23 modifies the pharmacological effects of angiotensin receptor blockade in experimental renal fibrosis","volume":"32","author":"de Jong","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.lfs.2020.118142_bb0250","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.bbi.2017.11.010","article-title":"Angiotensin receptor blocker irbesartan reduces stress-induced intestinal inflammation via AT1a signaling and ACE2-dependent mechanism in mice","volume":"69","author":"Yisireyili","year":"2018","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.lfs.2020.118142_bb0255","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20160344","article-title":"Differential renal effects of candesartan at high and ultra-high doses in diabetic mice-potential role of the ACE2\/AT2R\/Mas axis","volume":"36","author":"Callera","year":"2016","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.lfs.2020.118142_bb0260","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/hr.2014.49","article-title":"Role of angiotensin-converting enzyme 2\/angiotensin-(1-7)\/Mas axis in the hypotensive effect of azilsartan","volume":"37","author":"Iwanami","year":"2014","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.lfs.2020.118142_bb0265","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1042\/CS20120162","article-title":"Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions","volume":"123","author":"Burchill","year":"2012","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.lfs.2020.118142_bb0270","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2119\/molmed.2010.00111","article-title":"Angiotensin-converting enzyme (ACE) 2 overexpression ameliorates glomerular injury in a rat model of diabetic nephropathy: a comparison with ACE inhibition","volume":"17","author":"Liu","year":"2011","journal-title":"Mol. Med."},{"key":"10.1016\/j.lfs.2020.118142_bb0275","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1113\/expphysiol.2007.041855","article-title":"Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats","volume":"93","author":"Hamming","year":"2008","journal-title":"Exp. Physiol."},{"key":"10.1016\/j.lfs.2020.118142_bb0280","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.amjhyper.2007.05.008","article-title":"Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats","volume":"20","author":"Takeda","year":"2007","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.lfs.2020.118142_bb0285","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1291\/hypres.29.865","article-title":"Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme","volume":"29","author":"Agata","year":"2006","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.lfs.2020.118142_bb0290","doi-asserted-by":"crossref","first-page":"H1013","DOI":"10.1152\/ajpheart.00068.2005","article-title":"Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats","volume":"289","author":"Igase","year":"2005","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.lfs.2020.118142_bb0295","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1161\/01.HYP.0000124667.34652.1a","article-title":"Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors","volume":"43","author":"Ishiyama","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.lfs.2020.118142_bb0300","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1007\/s00125-008-0988-x","article-title":"Urinary mRNA expression of ACE and ACE2 in human type 2 diabetic nephropathy","volume":"51","author":"Wang","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.lfs.2020.118142_bb0305","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/HJH.0b013e32834f04b6","article-title":"Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications","volume":"30","author":"Soro-Paavonen","year":"2012","journal-title":"J. Hypertens."},{"key":"10.1016\/j.lfs.2020.118142_bb0310","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00726-014-1889-6","article-title":"Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors","volume":"47","author":"Vuille-dit-Bille","year":"2015","journal-title":"Amino Acids"},{"key":"10.1016\/j.lfs.2020.118142_bb0315","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1093\/eurheartj\/ehaa373","article-title":"Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors","volume":"41","author":"Sama","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.lfs.2020.118142_bb0320","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1016\/S2213-2600(20)30224-1","article-title":"SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors","volume":"8","author":"Milne","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.lfs.2020.118142_bb0325","doi-asserted-by":"crossref","DOI":"10.1093\/cvr\/cvaa106","article-title":"COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options","author":"Guzik","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.lfs.2020.118142_bb0330","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","article-title":"Renin-angiotensin-aldosterone system blockers and the risk of Covid-19","volume":"382","author":"Mancia","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2020.118142_bb0335","first-page":"2020","article-title":"ACE inhibitors, AT1 receptor blockers and COVID-19: clinical epidemiology evidences for a continuation of treatments","author":"Dauchet","year":"2020","journal-title":"The ACER-COVID study. medRxiv"},{"key":"10.1016\/j.lfs.2020.118142_bb0340","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","article-title":"Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19","volume":"382","author":"Reynolds","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2020.118142_bb0345","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2020.1855","article-title":"Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19)","author":"Mehta","year":"2020","journal-title":"JAMA Cardiol."},{"issue":"Suppl. 3","key":"10.1016\/j.lfs.2020.118142_bb0350","doi-asserted-by":"crossref","first-page":"S224","DOI":"10.1097\/01.ASN.0000032544.37147.AE","article-title":"Renal and cardiovascular protection in type 2 diabetes mellitus: angiotensin II receptor blockers","volume":"13","author":"Deferrari","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2020.118142_bb0355","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","article-title":"Association of Inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19","volume":"126","author":"Zhang","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.lfs.2020.118142_bb0360","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","article-title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","volume":"9","author":"Meng","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.lfs.2020.118142_bb0365","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(20)31030-8","article-title":"Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study","volume":"395","author":"de Abajo","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2020.118142_bb0370","article-title":"Association of renin-angiotensin-aldosterone system inhibitors with COVID-19-related outcomes in Korea: a nationwide population-based cohort study","author":"Jung","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.lfs.2020.118142_bb0375","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamacardio.2020.1624","article-title":"Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China","volume":"5","author":"Li","year":"2020","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.lfs.2020.118142_bb0380","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.120.15143","article-title":"Effects of ARBs and ACEIs on virus infection, inflammatory status and clinical outcomes in COVID-19 patients with hypertension: a single center retrospective study","volume":"76","author":"Yang","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.lfs.2020.118142_bb0385","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1164\/rccm.202002-0445OC","article-title":"COVID-19 with different severity: a multi-center study of clinical features","volume":"201","author":"Feng","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.lfs.2020.118142_bb0390","unstructured":"Peng YD, Meng K, Guan HQ, et al. [Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV]. Zhonghua Xin Xue Guan Bing Za Zhi 2020; 48:E4."},{"key":"10.1016\/j.lfs.2020.118142_bb0395","doi-asserted-by":"crossref","first-page":"430","DOI":"10.21037\/atm.2020.03.229","article-title":"The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension","volume":"8","author":"Huang","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.lfs.2020.118142_bb0400","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jacc.2020.05.040","article-title":"Ramipril in high risk patients with COVID-19","volume":"76","author":"Amat-Santos","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.lfs.2020.118142_bb0405","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMe2012924","article-title":"Inhibitors of the renin-angiotensin-aldosterone system and Covid-19","volume":"382","author":"Jarcho","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2020.118142_bb0410","article-title":"Estimation of RAAS-inhibitor effect on the COVID-19 outcome: a meta-analysis","author":"Pirola","year":"2020","journal-title":"J. Inf. Secur."},{"key":"10.1016\/j.lfs.2020.118142_bb0415","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1161\/HYPERTENSIONAHA.120.15572","article-title":"Decreased mortality of COVID-19 with renin-angiotensin-aldosterone system inhibitors therapy in patients with hypertension: a meta-analysis","volume":"76","author":"Guo","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.lfs.2020.118142_bb0420","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1097\/CCM.0b013e31828a6688","article-title":"Angiotensin-(1-7) protects from experimental acute lung injury","volume":"41","author":"Klein","year":"2013","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.lfs.2020.118142_bb0425","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/bph.13462","article-title":"Therapeutic time window for angiotensin-(1-7) in acute lung injury","volume":"173","author":"Supe","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2020.118142_bb0430","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/path.2987","article-title":"Acute respiratory distress syndrome leads to reduced ratio of ACE\/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist","volume":"225","author":"Wosten-van","year":"2011","journal-title":"J. Pathol."},{"key":"10.1016\/j.lfs.2020.118142_bb0435","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1161\/HYPERTENSIONAHA.114.03743","article-title":"Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism","volume":"64","author":"Deshotels","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.lfs.2020.118142_bb0440","unstructured":"U.S. National Library of Medicine. Coronavirus (COVID-19) ACEi\/ARB investigation (CORONACION). ClinicalTrials.gov Identifier: NCT04330300 [updated April 13, 2020]. Accessed at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04330300term=NCT04330300&draw=2&rank=1 on May 20, 2020."},{"key":"10.1016\/j.lfs.2020.118142_bb0445","unstructured":"U.S. National Library of Medicine. Efficacy of captopril in Covid-19 patients with severe acute respiratory syndrome (SARS) CoV-2 pneumonia (CAPTOCOVID). ClinicalTrials.gov Identifier: NCT04355429 [updated April 28, 2020]. Accessed at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04355429?term=NCT04355429&draw=2&rank=1 on May 20, 2020."},{"key":"10.1016\/j.lfs.2020.118142_bb0450","unstructured":"U.S. National Library of Medicine. Angiotensin converting enzyme inhibitors in treatment of Covid 19. ClinicalTrials.gov Identifier: NCT04345406 [updated April 14, 2020]. Accessed at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04345406?term=NCT04345406&draw=2&rank=1 on May 20, 2020."},{"key":"10.1016\/j.lfs.2020.118142_bb0455","unstructured":"U.S. National Library of Medicine. Losartan for patients with COVID-19 requiring hospitalization. ClinicalTrials.gov Identifier: NCT04312009 2020 [updated March 23, 2020]. Accessed at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04312009 on May 20, 2020."},{"key":"10.1016\/j.lfs.2020.118142_bb0460","unstructured":"U.S. National Library of Medicine. Angiotensin receptor blockers and angiotensin-converting enzyme inhibitors and adverse outcomes in patients with COVID19 (BRACE-CORONA). ClinicalTrials.gov Identifier: NCT04364893. [updated April 28, 2020]. Accessed at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04364893 on May 20, 2020."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320520308948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320520308948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T21:17:55Z","timestamp":1765228675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320520308948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":92,"alternative-id":["S0024320520308948"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2020.118142","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2020.118142","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"118142"}}